Posted On: 03/24/2016 8:49:19 PM
Post# of 72443
I wasn't bummed in the least because it didn't slow us down in the least. We are on the verge of multiple phase IIs and that was a Phase Ib and we are STILL making progress on lymphoma and multiple myeloma!!!!!!!!!!!! Woo hoo!!!
Anyway my .02 but :
"MD Anderson intends to utilize in vivo and in vitro methods to research specific pathways, gene expression, mechanism of action and apoptotic activity of Kevetrin in a range of concentrations and time points in both mutant and wild-type p53 Myeloma and Lymphoma cell lines. Research is also planned to evaluate Kevetrin against models of Multiple Myeloma cell lines that are resistant to bortezomib, lenalidomide and other FDA-approved chemotherapies. Additional studies will be conducted evaluating the anti-tumor activity of Kevetrin when used as a combination therapy with several FDA-approved"
"http://cellceutix.com/cellceutix-signs-material-transfer-agreement-for-research-of-kevetrin-in-lymphoma-and-multiple-myeloma-cancers-with-major-cancer-center/#sthash.x59hDYJr.dpbs
Anyway my .02 but :
"MD Anderson intends to utilize in vivo and in vitro methods to research specific pathways, gene expression, mechanism of action and apoptotic activity of Kevetrin in a range of concentrations and time points in both mutant and wild-type p53 Myeloma and Lymphoma cell lines. Research is also planned to evaluate Kevetrin against models of Multiple Myeloma cell lines that are resistant to bortezomib, lenalidomide and other FDA-approved chemotherapies. Additional studies will be conducted evaluating the anti-tumor activity of Kevetrin when used as a combination therapy with several FDA-approved"
"http://cellceutix.com/cellceutix-signs-material-transfer-agreement-for-research-of-kevetrin-in-lymphoma-and-multiple-myeloma-cancers-with-major-cancer-center/#sthash.x59hDYJr.dpbs
(3)
(1)
***On 02/26/2016 at 8:33 am Scottsmith admited to posting under 5 aliases but his post was subsequently deleted. I have a screen shot and will email it to anyone interested.
Scroll down for more posts ▼
